AUROBINDO PHARMA LTD. - Information Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

The Board of Directors of Aurobindo Pharma Limited ('the Company') at its meeting held today i.e. February 27, 2021, has approved the following:<BR> 1) Transfer of all equity shares held in Lyfius Pharma Private Limited, a wholly owned subsidiary of the Company, to Aurobindo Antibiotics Private Limited, another wholly owned subsidiary of the Company.<BR> 2) Transfer of all equity shares held in Qule Pharma Private Limited, a wholly owned subsidiary of the Company, to Aurobindo Antibiotics Private Limited, another wholly owned subsidiary of the Company.<BR> 3) Transfer of business undertaking comprised in Unit-10, on a going concern basis, to APL Healthcare Limited, a wholly owned subsidiary of the Company. <BR>